Monoclonal Antibodies for COVID-19 Treatment: Is It an Option in Indonesia?
More than three years after Coronavirus disease 2019 (COVID-19), an infectious disease caused by the severe acute respiratory syndrome coronavirus 2 (SARS-COV2), was declared pandemic by World Health Organization, report of COVID-19 hospitalization and death have been decreasing. Even though COVID-1...
Main Author: | Alvina Widhani |
---|---|
Format: | Article |
Language: | English |
Published: |
Interna Publishing
2023-07-01
|
Series: | Acta Medica Indonesiana |
Subjects: | |
Online Access: | https://actamedindones.org/index.php/ijim/article/view/2582 |
Similar Items
-
Monoclonal Antibodies for Pre- and Postexposure Prophylaxis of COVID-19: Review of the Literature
by: Serena Vita, et al.
Published: (2022-08-01) -
Monoclonal Antibodies and Flaviviruses: a Possible Option?
by: Nicasio Mancini
Published: (2022-06-01) -
Use of Monoclonal Antibodies in Pregnant Women Infected by COVID-19: A Case Series
by: Pietro Crispino, et al.
Published: (2023-07-01) -
Monoclonal antibodies as COVID-19 prophylaxis therapy in immunocompromised patient populations
by: Juthaporn Cowan, et al.
Published: (2023-09-01) -
Retrospective Analysis of Vaccinated and Unvaccinated COVID-19 Patients Treated with Monoclonal Antibodies (mAb) and Their Emergent Needs (RAVEN)
by: Gordana Simeunovic, et al.
Published: (2023-03-01)